HOUSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today issued the following letter to shareholders. Fellow Shareholders, Looking back on 2025, I'm reminded of something I've always believed: the best way to predict the future is to invent it. At ...

HOUSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the 9th Annual BFC Global Healthcare Business Development and Investment Conference taking ...

FSdC demonstrated statistically significant and superior improvement in disc preservation and structural integrity compared to other treatmentsHOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced positive preclinical results for FSdC ...

HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the filing of a Phase 1/2 Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) seeking regulatory clearance to initiate clinical trials of CY ...

As filed with the Securities and Exchange Commission on December 23, 2025. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FibroBiologics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 455 E. Medical Center Blvd. Suite 300 Houston, Texas 77598 (281) 671-5150 Delaware 2834 86-3329066 (Prim ...

HOUSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 5,227,275 shares of its common stock ...

Core Viewpoint - FibroBiologics, Inc. has announced a registered direct offering of 5,227,275 shares of common stock at $0.33 per share, along with a concurrent private placement of unregistered warrants for the same number of shares at the same exercise price, aiming to raise approximately $1.7 million in gross proceeds [1][3]. Group 1: Offering Details - The company will issue 5,227,275 shares of common stock at an offering price of $0.33 per share in a registered direct offering [1]. - Concurrently, unregistered warrants will be issued to purchase up to 5,227,275 shares at an exercise price of $0.33 per share, which will be exercisable upon stockholder approval [1]. - The closing of the offering is expected on or about December 16, 2025, subject to customary closing conditions [1]. Group 2: Financial Implications - The aggregate gross proceeds from the offering are expected to be approximately $1.7 million before deducting fees and expenses [3]. - If the unregistered warrants are fully exercised, additional gross proceeds of approximately $1.7 million could be realized [3]. - The net proceeds from the offering will be used for working capital and general corporate purposes [3]. Group 3: Regulatory Information - The shares offered in the registered direct offering are being made under a "shelf" registration statement that became effective on February 10, 2025 [4]. - The unregistered warrants and shares issuable upon their exercise are being offered in a private placement and have not been registered under the Securities Act [5]. Group 4: Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblast cells and materials, holding over 270 patents [9]. - The company is involved in various clinical pathways, including wound healing, multiple sclerosis, and cancer, representing advancements in cell therapy and tissue regeneration [9].

On Wednesday, FibroBiologics, Inc. (NASDAQ:FBLG) submitted a new patent application with the U.S. Patent and Trademark Office (USPTO).The patent application covers a proprietary fibroblast-derived therapy platform for use in orthopedic and musculoskeletal conditions, including degenerative disc repair, cartilage repair, and joint restoration.The application, if granted, strengthens the protection for the company’s fibroblast technology that leverages fibroblast cells, spheroids, and/or fibroblast-differenti ...

Core Insights - FibroBiologics has submitted a new patent application for a fibroblast-derived therapy platform aimed at orthopedic and musculoskeletal conditions, which includes degenerative disc repair and cartilage repair [1][2][3] - The application, if granted, will enhance the protection of the company's innovative fibroblast technology, which has shown promise in preclinical studies for integrating with native tissue and promoting regeneration [2][3] - The CEO of FibroBiologics emphasized that this patent application is a significant advancement in expanding the company's focus from chronic wounds to the structural repair of the musculoskeletal system, targeting large markets in degenerative disc disease and joint disease [3] Company Overview - FibroBiologics is a clinical-stage biotechnology company based in Houston, specializing in developing treatments and potential cures for chronic diseases using fibroblast cells and materials [4] - The company holds over 270 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, and orthopedics [4] - FibroBiologics aims to be at the forefront of medical advancements in cell therapy and tissue regeneration [4]

Core Viewpoint - FibroBiologics has successfully repaid all outstanding convertible promissory notes, strengthening its balance sheet and eliminating further dilution from conversions [1][2][3] Financial Developments - The company has paid off the convertible promissory notes issued to Yorkville, which were part of a Standby Equity Purchase Agreement (SEPA) allowing the sale of up to $25 million in common stock [1][2] - The first $15 million was advanced in three equal tranches, and with the repayment, there will be no further conversions into shares [2] - The SEPA remains active until December 20, 2026, permitting the company to sell an additional $10 million of its common stock under certain conditions [2] Strategic Focus - The repayment of convertible debt allows the company to concentrate on advancing its clinical programs, particularly the initiation of first-in-human trials [3] - The company is preparing to start a Phase 1/2 clinical trial for its fibroblast-based product candidate CYWC628 in diabetic foot ulcer patients in early 2026 [4] - Additionally, the company plans to submit Investigational New Drug applications for treatments targeting psoriasis and multiple sclerosis [4] Company Overview - FibroBiologics is a clinical-stage biotechnology company based in Houston, focusing on developing therapeutics for chronic diseases using fibroblast cells [8] - The company holds over 270 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, and cancer [8]